Cogent has strengthened its leadership team with the recent appointments of Ray Frost and Adam Boyd, Ph.D. Ray Frost has taken on the role of Senior Vice President of Market Access. Before joining Cogent, Frost held the position of Vice President of Market Access at both Ono Pharma USA and Zealand Pharma, bringing a wealth of experience and industry knowledge to his new role.
In parallel, Adam Boyd, Ph.D. has been appointed as the Senior Vice President of Corporate Strategy. Dr. Boyd transitions to this new role after his tenure as Vice President of Biometrics at Intellia Therapeutics, where he was instrumental in advancing strategic initiatives.
These strategic hires highlight Cogent's commitment to enhancing their market positioning and corporate development as they navigate the competitive landscape in the industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Cogent Biosciences Inc (COGT, Financial) is $16.10 with a high estimate of $24.00 and a low estimate of $8.00. The average target implies an upside of 256.98% from the current price of $4.51. More detailed estimate data can be found on the Cogent Biosciences Inc (COGT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Cogent Biosciences Inc's (COGT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
